Limits...
Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women.

Abdou AM, Watabe K, Yamane T, Isono T, Okamura Y, Kawahito S, Takeshima K, Masuda K, Kim M - Food Sci Nutr (2014)

Bottom Line: The main objective of this study was to verify the effect of oral intake of a yolk-derived peptide preparation (HYP) obtained by enzymatic hydrolysis of yolk water-soluble protein on bone markers and bone density in 65 perimenopausal women with an average age of 47.6 ± 5.2 years.After 6 months, BMD in the test HYP group maintained at healthy numerical values whereas BMD values were decreased in other groups.Hence HYP would be an antiosteoporotic agent originated from natural food to maintain bone health, especially for women.

View Article: PubMed Central - PubMed

Affiliation: Pharma Foods International Co., Ltd. Kyoto, 615-8245, Japan.

ABSTRACT
The main objective of this study was to verify the effect of oral intake of a yolk-derived peptide preparation (HYP) obtained by enzymatic hydrolysis of yolk water-soluble protein on bone markers and bone density in 65 perimenopausal women with an average age of 47.6 ± 5.2 years. Subjects were divided into three groups, and then enrolled in a 6-month, randomized, double-blind clinical trial. Bone formation and resorption markers were measured at 0, 3, and 6 months, while bone mineral density (BMD) in the lumbar spines was measured at 0 and 6 months. Although the bone formation marker levels showed the similarity changes among the groups, bone resorption markers in the test HYP group were significantly decreased after 3 and 6 months in comparison to other groups (P < 0.05). After 6 months, BMD in the test HYP group maintained at healthy numerical values whereas BMD values were decreased in other groups. Hence HYP would be an antiosteoporotic agent originated from natural food to maintain bone health, especially for women.

No MeSH data available.


Related in: MedlinePlus

Bone mineral density (BMD) change rate (percent change from baseline; mean ± SEM) in women in WA-1, WA-2, and WA-3 groups after 0 and 6 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4048604&req=5

fig04: Bone mineral density (BMD) change rate (percent change from baseline; mean ± SEM) in women in WA-1, WA-2, and WA-3 groups after 0 and 6 months.

Mentions: Moreover, WA-3 group showed inhibition in the loss of bone density and BMD of lumbar spines maintained healthy numerical values, while values in WA-1 and WA-2 groups showed reduction in BMD values at sixth month (Fig. 4). The measurement of BMD is the most important tool for monitoring response to therapy in osteoporotic patients. This technology provides a sensitive means for diagnosing decreased bone mass and predicting fracture. Measurement of BMD using dual energy X-ray absorptometry (DEXA) is perhaps most useful, having an accuracy exceeding 95%, especially for the femoral and lumbar spines. Thus, BMD is considered the gold standard for diagnosis and treatment monitoring and, therefore, used for most clinical studies (Elliott and Binkley 2004). In this study, HYP exhibited a slight increase in BMD compared to both baseline and other groups at 6 months. It has been reported that after initiation of antiresorptive therapy, either stability or an increase in bone mass is considered as a positive response, in that stable BMD is associated with reduced fracture risk (Hochberg et al. 2002). However, using BMD to determine a response to therapy may take 1–2 years. Therefore, BMD findings for HYP intake in this study will need more investigations in a large-scale human trial for a longer period.


Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women.

Abdou AM, Watabe K, Yamane T, Isono T, Okamura Y, Kawahito S, Takeshima K, Masuda K, Kim M - Food Sci Nutr (2014)

Bone mineral density (BMD) change rate (percent change from baseline; mean ± SEM) in women in WA-1, WA-2, and WA-3 groups after 0 and 6 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4048604&req=5

fig04: Bone mineral density (BMD) change rate (percent change from baseline; mean ± SEM) in women in WA-1, WA-2, and WA-3 groups after 0 and 6 months.
Mentions: Moreover, WA-3 group showed inhibition in the loss of bone density and BMD of lumbar spines maintained healthy numerical values, while values in WA-1 and WA-2 groups showed reduction in BMD values at sixth month (Fig. 4). The measurement of BMD is the most important tool for monitoring response to therapy in osteoporotic patients. This technology provides a sensitive means for diagnosing decreased bone mass and predicting fracture. Measurement of BMD using dual energy X-ray absorptometry (DEXA) is perhaps most useful, having an accuracy exceeding 95%, especially for the femoral and lumbar spines. Thus, BMD is considered the gold standard for diagnosis and treatment monitoring and, therefore, used for most clinical studies (Elliott and Binkley 2004). In this study, HYP exhibited a slight increase in BMD compared to both baseline and other groups at 6 months. It has been reported that after initiation of antiresorptive therapy, either stability or an increase in bone mass is considered as a positive response, in that stable BMD is associated with reduced fracture risk (Hochberg et al. 2002). However, using BMD to determine a response to therapy may take 1–2 years. Therefore, BMD findings for HYP intake in this study will need more investigations in a large-scale human trial for a longer period.

Bottom Line: The main objective of this study was to verify the effect of oral intake of a yolk-derived peptide preparation (HYP) obtained by enzymatic hydrolysis of yolk water-soluble protein on bone markers and bone density in 65 perimenopausal women with an average age of 47.6 ± 5.2 years.After 6 months, BMD in the test HYP group maintained at healthy numerical values whereas BMD values were decreased in other groups.Hence HYP would be an antiosteoporotic agent originated from natural food to maintain bone health, especially for women.

View Article: PubMed Central - PubMed

Affiliation: Pharma Foods International Co., Ltd. Kyoto, 615-8245, Japan.

ABSTRACT
The main objective of this study was to verify the effect of oral intake of a yolk-derived peptide preparation (HYP) obtained by enzymatic hydrolysis of yolk water-soluble protein on bone markers and bone density in 65 perimenopausal women with an average age of 47.6 ± 5.2 years. Subjects were divided into three groups, and then enrolled in a 6-month, randomized, double-blind clinical trial. Bone formation and resorption markers were measured at 0, 3, and 6 months, while bone mineral density (BMD) in the lumbar spines was measured at 0 and 6 months. Although the bone formation marker levels showed the similarity changes among the groups, bone resorption markers in the test HYP group were significantly decreased after 3 and 6 months in comparison to other groups (P < 0.05). After 6 months, BMD in the test HYP group maintained at healthy numerical values whereas BMD values were decreased in other groups. Hence HYP would be an antiosteoporotic agent originated from natural food to maintain bone health, especially for women.

No MeSH data available.


Related in: MedlinePlus